Metagenomi Therapeutics, Inc. (MGX)
NASDAQ: MGX · Real-Time Price · USD
1.110
+0.050 (4.72%)
At close: Oct 1, 2026, 4:00 PM EDT
1.105
-0.005 (-0.45%)
After-hours: Oct 1, 2026, 4:10 PM EDT
Metagenomi Therapeutics Stock Forecast
MGX's stock price has decreased by -53.38% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 5 analysts polled by S&P Global, Metagenomi Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $7.00. The average 1-year stock price forecast is 530.63% higher than the current stock price, while the lowest is $5.00 (+350.45%) and the highest is $9.00 (+710.81%).
Price Target: $7.00 (+530.63%)
Analyst Consensus: Strong Buy
Price Target
Chart* Price targets were last updated on Aug 11, 2026.
Analyst Ratings
The average analyst rating for Metagenomi Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 3 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 4 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst J.P. Morgan No rating | J.P. Morgan | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Aug 18, 2026 |
| TD Cowen | TD Cowen | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Aug 12, 2026 |
| Wells Fargo | Wells Fargo | Buy Reiterates $9 → $7 | Buy | Reiterates | $9 → $7 | +530.63% | Aug 11, 2026 |
| Chardan Capital | Chardan Capital | Buy Maintains $5 | Buy | Maintains | $5 | +350.45% | Aug 11, 2026 |
Financial Forecast
Revenue This Year
4.15M
from 25.21M
Decreased by -83.55%
Revenue Next Year
7.48M
from 4.15M
Increased by 80.23%
EPS This Year
-2.42
from -2.36
EPS Next Year
-1.84
from -2.42
EPS and Forward PE are based on non-GAAP adjusted numbers.